BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 23775437)

  • 1. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.
    Downes MR; Torlakovic EE; Aldaoud N; Zlotta AR; Evans AJ; van der Kwast TH
    J Clin Pathol; 2013 Sep; 66(9):779-86. PubMed ID: 23775437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do HOXB13 and P63 have a role in differentiating poorly differentiated prostatic carcinoma from urothelial high-grade carcinoma?
    Alshenawy HA; Saied E
    APMIS; 2015 Sep; 123(9):772-8. PubMed ID: 26200506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas.
    Mohanty SK; Smith SC; Chang E; Luthringer DJ; Gown AM; Aron M; Amin MB
    Am J Clin Pathol; 2014 Aug; 142(2):173-83. PubMed ID: 25015857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
    Kunju LP; Mehra R; Snyder M; Shah RB
    Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate.
    Ud Din N; Qureshi A; Mansoor S
    Indian J Pathol Microbiol; 2011; 54(1):59-62. PubMed ID: 21393879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
    Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
    Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
    Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
    Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
    Gordetsky J; Epstein JI
    Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
    Genega EM; Hutchinson B; Reuter VE; Gaudin PB
    Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of p63 and high molecular weight cytokeratin in the distinction between urothelial carcinoma with prostatic stromal invasion and urothelial carcinoma with colonisation of prostatic ducts and acini.
    Chastain EC; Oliva IV; Osunkoya AO
    Pathology; 2012 Apr; 44(3):199-203. PubMed ID: 22406481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract.
    Gulmann C; Paner GP; Parakh RS; Hansel DE; Shen SS; Ro JY; Annaiah C; Lopez-Beltran A; Rao P; Arora K; Cho Y; Herrera-Hernandez L; Alsabeh R; Amin MB
    Hum Pathol; 2013 Feb; 44(2):164-72. PubMed ID: 22995333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature.
    Varma M; Jasani B
    Histopathology; 2005 Jul; 47(1):1-16. PubMed ID: 15982318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.
    Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE
    Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases.
    Martínez-Rodríguez M; Ramos D; Soriano P; Subramaniam M; Navarro S; Llombart-Bosch A
    Int J Surg Pathol; 2007 Apr; 15(2):213-8. PubMed ID: 17478786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
    Epstein JI; Egevad L; Humphrey PA; Montironi R;
    Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.
    Miyamoto H; Yao JL; Chaux A; Zheng Y; Hsu I; Izumi K; Chang C; Messing EM; Netto GJ; Yeh S
    BJU Int; 2012 Jun; 109(11):1716-26. PubMed ID: 22221549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.
    Mhawech P; Uchida T; Pelte MF
    Hum Pathol; 2002 Nov; 33(11):1136-40. PubMed ID: 12454820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of uroplakin II expression as a marker of urothelial carcinoma.
    Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
    Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.
    Lin X; Zhu B; Villa C; Zhong M; Kundu S; Rohan SM; Yang XJ
    Hum Pathol; 2014 Sep; 45(9):1824-9. PubMed ID: 24993315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.